Guidant Bio develops the Navigated Delivery™ platform, a fully human modular system that extends serum half‑life and enhances tumor accumulation of biologic therapeutics. The technology enables delivery of diverse payloads such as cytokines, interleukins, and antibodies, with candidates like GDT‑001 in Phase 1 trials for solid tumors. Guidant Bio offers a plug‑and‑play platform for co‑development and licensing partnerships across immuno‑oncology and precision oncology.
Funding
Funding not disclosed
Founders
Product
Problem
Systemic administration of cytokine immunotherapies such as IL‑12 often triggers severe immune‑related toxicities and exhibits short serum half‑life, limiting their ability to convert immunologically “cold” tumors into responsive “hot” lesions.
Solution
Guidant BioTherapeutics addresses these limitations with its proprietary Navigated Delivery™ platform built on a fully human albumin‑binding (F H AB) construct. By covalently linking therapeutic payloads to an albumin‑binding fragment, the platform leverages the natural FcRn‑mediated recycling and tumor‑associated albumin accumulation pathways to extend systemic exposure up to ten‑fold and concentrate the drug within the tumor microenvironment. This targeted delivery reduces off‑target distribution and mitigates systemic immune activation while preserving the biological activity of cytokine payloads. The lead candidate, GDT‑001 (IL‑12‑F H AB), is in Phase 1 trials for advanced solid tumors and in combination with trabectedin for soft‑tissue sarcoma, demonstrating the platform’s ability to turn “cold” tumors “hot.” The modular nature of the technology enables rapid adaptation to a broad range of biologic payloads, including other interleukins, growth factors, peptides, antibodies, and antibody‑drug conjugates, supporting co‑development and licensing partnerships.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing oncology biologics, as well as academic and clinical research groups seeking a tumor‑targeted delivery platform for cytokine‑based immunotherapies.
Features
- Albumin‑binding fragment engineered to attach at a specific site on native albumin, preserving FcRn engagement and natural recycling
- Up to 10× extension of serum half‑life and enhanced tumor accumulation through FcRn‑mediated transport and inflamed‑tissue uptake
- Modular “plug‑and‑play” architecture compatible with cytokines, growth factors, peptides, antibodies, and ADC payloads
- Reduced systemic cytokine exposure minimizes immune‑related adverse events while maintaining local immunostimulatory activity
- Clinical‑stage IL‑12 fusion (GDT‑001) demonstrated safety and activity in Phase 1 monotherapy and combination studies with trabectedin
- Scalable manufacturing of fully human protein constructs for rapid preclinical and clinical development